MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 490 participants.

Also called NCT06543082

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 490 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06543082
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06543082. Allocation not applicable; no masking; primary purpose treatment. Start 2024-08-05 (actual); primary completion 2028-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study
Acronym
MACT II
Condition
Acute Coronary Syndrome
Intervention (Drug)
Colchicine 0.6 mg
Lead sponsor
CHA University (class: other)
Collaborator
Biotronik SE & Co. KG (class: industry)

Record details

Record id
cardio:ct-nct06543082
Content hash
9ff4d6815c198969bbf864071ad72b1011c8583b82d5e04764a76b9140e51e53